Header cover image
  • Investing Ideas
  • Polish Pharmaceuticals & Biotech Healthy potentially undervalued

Polish Pharmaceuticals & Biotech Healthy potentially undervalued

Results

1

1 new

Companies which are potentially undervalued and in an acceptable financial position.

1 companies

Ryvu Therapeutics

Market Cap: zł361.1m

A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.

New

RVU

zł15.40

7D

7.8%

1Y

-46.5%